

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10575905	
	Filing Date		2007-04-30	
	First Named Inventor	Haiton et al.		
	Art Unit	1644		
	Examiner Name	Ilia I. Ouspenski		
Attorney Docket Number		14875-0161US1		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5945311		1999-08-31	LINDHOFER et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20090324589		2009-12-31	IGAWA et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1510943	EP		2005-03-02	SAITO et al.		<input type="checkbox"/>
	2	1870459	EP		2007-12-26	IGAWA et al.		<input type="checkbox"/>
	3	09506001	JP		1997-06-17	LINDHOFER et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575905
Filing Date	2007-04-30
First Named Inventor	Hatton et al.
Art Unit	1644
Examiner Name	Iliia I. Ouspenski
Attorney Docket Number	14875-0161US1

4	9533844	WO		1995-12-14	LINDHOFFER et al.	<input type="checkbox"/>
5	9627011	WO		1996-09-06	CARTER et al.	<input type="checkbox"/>
6	9803546	WO		1998-01-29	BOONE et al.	<input type="checkbox"/>
7	2006106805	WO		2006-10-12	IGAWA et al.	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	FISH & RICHARDSON P.C., Amendment in Reply to Action dated September 24, 2009 in U.S. App. Ser. No. 10/575,193, filed March 24, 2010, 19 pages	<input type="checkbox"/>
	2	U.S. EXAMINER MICHEL EDWARD SZPERKA, USPTO Final Office Action in U.S. App. Ser. No. 10/575,193, mailed June 23, 2010, 18 pages	<input type="checkbox"/>
	3	SCHMIDT et al., Human Physiology, Moscow, 2:431-436 (1996), and English translation: SCHMIDT et al., "Hemostasis and Coagulation," Human Physiology, R.F. Schmidt, G. Thews (Eds.), Second, Completely Revised Edition, 418-423 [translated by Marguerite A. Biederman-Thorson], Springer-Verlag, 1989	<input checked="" type="checkbox"/>
	4	SCHMIDT et al., Human Physiology, Moscow, 3:764 (1996), and English translation: SCHMIDT et al., "Enzymes of the pancreatic juice," Human Physiology, R.F. Schmidt, G. Thews (Eds.), Second, Completely Revised Edition, 716 [translated by Marguerite A. Biederman-Thorson], Springer-Verlag, 1989	<input checked="" type="checkbox"/>
	5	ADAMS et al., "Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab," Cancer Immunol. Immunother., 55:717-727 (2006)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575905
Filing Date	2007-04-30
First Named Inventor	Hatton et al.
Art Unit	1644
Examiner Name	Iliia I. Ouspenski
Attorney Docket Number	14875-0161US1

6	BINZ et al., "Engineering novel binding proteins from nonimmunoglobulin domains," Nat. Biotechnol., 23:1257-68 (2005)	<input type="checkbox"/>
7	BRANDEN and TOOZE, "Recognition of Foreign Molecules by the Immune System," Introduction to Protein Structure, 2d Ed., Garland Publishing, pp. 299-323 (1999)	<input type="checkbox"/>
8	COMPER and GLASGOW, "Charge selectivity in kidney ultrafiltration," Kidney Int., 47:1242-51 (1995)	<input type="checkbox"/>
9	COUTO et al., "Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and In Vivo and In Vitro Characterization," Cancer Res., 55:1717-22 (1995)	<input type="checkbox"/>
10	DEEN et al., "Structural determinants of glomerular permeability," Am. J. Physiol. Renal. Physiol., 281:F579-F596 (2001)	<input type="checkbox"/>
11	DEL RIO et al., "An Engineered Penicillin Acylase with Altered Surface Charge Is More Stable in Alkaline pH," Ann. NY Acad. Sci., 799:61-64 (1996)	<input type="checkbox"/>
12	DILLON et al., "Structural and functional characterization of disulfide isoforms of the human IgG2 subclass," J. Biol. Chem., 283:16206-15 (2008)	<input type="checkbox"/>
13	EWERT et al., "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering," Methods, 34:184-199 (2004)	<input type="checkbox"/>
14	GHEITIE and WARD, "FcRn: the MHC class I-related receptor that is more than an IgG transporter," Immunol. Today, 18:592-598 (1997)	<input type="checkbox"/>
15	GHEITIE et al., "Increasing the serum persistence of an IgG fragment by random mutagenesis," Nat. Biotechnol., 15:637-640 (1997)	<input type="checkbox"/>
16	GHEITIE et al., "Multiple roles for the major histocompatibility complex class I-related receptor FcRn," Annu. Rev. Immunol., 18:739-766 (2000)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575905
Filing Date	2007-04-30
First Named Inventor	Hatton et al.
Art Unit	1644
Examiner Name	Iliia I. Ouspenski
Attorney Docket Number	14875-0161US1

17	GOBBURU et al., "Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys," J. Pharmacol. Exp. Ther., 266:925-930 (1998)	<input type="checkbox"/>
18	GOODE et al., "The glomerular basement membrane charge-selectivity barrier: an oversimplified concept?," Nephrol. Dial. Transplant., 11:1714-16 (1996)	<input type="checkbox"/>
19	GRAVES et al., "Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody," Clin. Cancer Res., 5:899-908 (1999)	<input type="checkbox"/>
20	GUPTA et al., "Affinity chromatography and co-chromatography of bispecific monoclonal antibody immunoconjugates," J. Biochem. Biophys. Methods, 51:203-216 (2002)	<input type="checkbox"/>
21	HANSON et al., "Catalytic antibodies and their applications," Curr. Opin. Biotechnol., 16:631-636 (2005)	<input type="checkbox"/>
22	HE et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin," J. Immunol., 160:1029-35 (1998)	<input type="checkbox"/>
23	HINTON et al., "An engineered human IgG1 antibody with longer serum half-life," J. Immunol., 176:346-356 (2006)	<input type="checkbox"/>
24	ITO et al., "The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values," FEBS Lett., 309:85-88 (1992)	<input type="checkbox"/>
25	KASHMIRI et al., "Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49," Hybridoma, 14:461-473 (1995)	<input type="checkbox"/>
26	KHAWLI et al., "Improved tumor localization and radiomaging with chemically modified monoclonal antibodies," Cancer Biother. Radiopharm., 11:203-215 (1996)	<input type="checkbox"/>
27	KIM et al., "Antibody Engineering for the Development of Therapeutic Antibodies," Mol. Cells, 20:17-29 (2005)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575905
Filing Date	2007-04-30
First Named Inventor	Hatton et al.
Art Unit	1644
Examiner Name	Ilia I. Ouspenski
Attorney Docket Number	14875-0161US1

28	KIM et al., "Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-tac monoclonal antibody labeled with ^{99m} Tc," Bioconjugate Chem., 10:447-453 (1999)	<input type="checkbox"/>
29	KIM et al., "Lowering of pI by acylation improves the renal uptake of ^{99m} Tc-labeled anti-Tac dsFv: effect of different acylating reagents," Nucl. Med. Biol., 29:795-801 (2002)	<input type="checkbox"/>
30	KOBAYASHI et al., "The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points," Cancer Res., 59:422-430 (1999)	<input type="checkbox"/>
31	KREUTZ et al., "Efficient bispecific monoclonal antibody purification using gradient thiophilic affinity chromatography," J. Chromatogr. B, 714:161-170 (1998)	<input type="checkbox"/>
32	LINDHOFER et al., "Preferential Species-Restricted Heavy/Light Chain Pairing in Rat/Mouse Quadromas," J. Immunol., 155:219-225 (1995)	<input type="checkbox"/>
33	LOBO et al., "Antibody pharmacokinetics and pharmacodynamics," J. Pharm. Sci., 93:2645-66 (2004)	<input type="checkbox"/>
34	MANZKE et al., "Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography," J. Immunol. Methods, 208:65-73 (1997)	<input type="checkbox"/>
35	MARTIN et al., "Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding," Mol. Cell, 7:867-877 (2001)	<input type="checkbox"/>
36	MARVIN et al., "Recombinant approaches to IgG-like bispecific antibodies," Acta. Pharmacol. Sin., 26:649-658 (2005)	<input type="checkbox"/>
37	MARVIN et al., "Redesigning an antibody fragment for faster association with its antigen," Biochemistry, 42:7077-83 (2003)	<input type="checkbox"/>
38	MERCHANT et al., "An efficient route to human bispecific IgG," Nat. Biotechnol., 16:677-681 (1998)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575905
Filing Date	2007-04-30
First Named Inventor	Hatton et al.
Art Unit	1644
Examiner Name	Iliia I. Ouspenski
Attorney Docket Number	14875-0161US1

39	ONDA et al., "Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity," Cancer Res., 61:5070-77 (2001)	<input type="checkbox"/>
40	PAVLINKOVA et al., "Charge-modified single chain antibody constructs of monoclonal antibody CC49: Generation, characterization, pharmacokinetics, and biodistribution analysis," Nucl. Med. Biol., 26:27-34 (1999)	<input type="checkbox"/>
41	PAVLOU et al., "The therapeutic antibodies market to 2008," Eur. J. Pharm. Biopharm., 59:389-396 (2005)	<input type="checkbox"/>
42	PODUSLO et al., "Polyamine modification increases the permeability of proteins at the blood – nerve and blood-brain barriers," J. Neurochem., 66:1599-1609 (1996)	<input type="checkbox"/>
43	RAJPAL et al., "A general method for greatly improving the affinity of antibodies by using combinatorial libraries," Proc. Natl. Acad. Sci. USA, 102:8466-71 (2005)	<input type="checkbox"/>
44	RATHANASWAMI et al., "Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8," Biochem. Biophys. Res. Commun., 334:1004-13 (2005)	<input type="checkbox"/>
45	REICHERT et al., "Monoclonal antibody successes in the clinic," Nat. Biotechnol., 23:1073-78 (2005)	<input type="checkbox"/>
46	SAL-MAN et al., "Arginine mutations within a transmembrane domain of Tar, an Escherichia coli aspartate receptor, can drive homodimer dissociation and heterodimer association in vivo," Biochem. J., 385:29-36 (2005)	<input type="checkbox"/>
47	SCHAEFFER et al., "The Rat Glomerular Filtration Barrier Does Not Show Negative Charge Selectivity," Microcirculation, 9:329-342 (2002)	<input type="checkbox"/>
48	SEGAL et al., "Bispecific antibodies in cancer therapy," Curr. Opin. Immunol., 11:558-562 (1999)	<input type="checkbox"/>
49	SHAUL, "Exploring the charge space of protein-protein association: a proteomic study," Proteins, 60:341-352 (2005)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575905
Filing Date	2007-04-30
First Named Inventor	Hatton et al.
Art Unit	1644
Examiner Name	Iliia I. Ouspenski
Attorney Docket Number	14875-0161US1

50	SHIELDS et al., "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R," J. Biol. Chem., 276:6591-6604 (2001)	<input type="checkbox"/>
----	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.